1 not yet recruiting, 1 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow Phase I dose escalation: new trials by email Literature Review of Phase I dose escalation trials Research Report on Phase I dose escalation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors Phase I dose escalation, Phase I: Dose Expansion, phase II - Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | Not yet recruiting | Suzhou Genhouse Bio Co., Ltd. | 152 | 2026-02-24 | 2026-03-03 |
| TSN222 in Subjects With Advanced Solid Tumors or Lymphomas Phase I dose escalation, Phase II-HNSCC, Phase II-Advanced melanoma - Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | Phase 1 / Phase 2 | Unknown | Tyligand Bioscience (Shanghai) Limited | 162 | 2023-07-26 | 2024-07-29 |
Lymphoma (1) · Neoplasm Metastasis (1)
Suzhou Genhouse Bio Co., Ltd. (1) · Tyligand Bioscience (Shanghai) Limited (1)
China (2)
Jian Zhang (1)